At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 206 enrolled
Drug / intervention
Lebrikizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Lebrikizumab for Atopic Dermatitis. Completed, enrolled 206 participants across 70 sites in 4 countries.
Detailed Summary
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to \<18 years weighing ≥40 kilograms) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, Poland, United States
CollaboratorsDermira, Inc.
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionApr 2022
Study CompletionJun 2022
TodayJul 2026
First PostedJan 31, 2020
Enrollment StartFeb 11, 2020
Primary CompletionApr 20, 2022
Study CompletionJun 22, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.4 years ago
Interventions
Lebrikizumabbiological
Subcutaneous injection